Jingchuan Guo1, Ashley I Naimi2, Maria M Brooks2, Matthew F Muldoon3, Trevor J Orchard2, Tina Costacou2. 1. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA. Electronic address: jig38@pitt.edu. 2. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA. 3. Heart and Vascular Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Abstract
PURPOSE: We assessed the extent of cardiovascular benefit of renin-angiotensin system (RAS) inhibition beyond lowering blood pressure (BP) and albuminuria in type 1 diabetes (T1D). METHODS: This cohort study included 605 T1D participants from the Pittsburgh Epidemiology of Diabetes Complications study without baseline coronary artery disease (CAD). Participant follow-up extended through 25 years. We implemented marginal structural models to estimate total effect of and controlled direct effect by isolating the role of BP or albuminuria in mediating the relation between RAS inhibitors and CAD. RESULTS: Total effect of longitudinal RAS inhibition treatment was associated with 38% decreased CAD risk (HR [95% CI]: 0.62 [0.23, 1.77]). The controlled direct effect of RAS inhibition was a 27% risk reduction (HR: 0.73 [0.20, 2.59]) when isolating the role of BP and 26% risk reduction (HR: 0.74 [0.16, 3.35]) when isolating the role of albuminuria. The mediation proportion for each 10 mm Hg systolic BP and each 1 log unit of albumin excretion rate were 34% and 37%, respectively. CONCLUSION: Our findings suggest that BP regulation and albuminuria reduction can only partially explain cardiovascular benefit of RAS inhibition on CAD in T1D, supporting the assertion that RAS inhibitors provide additional cardioprotection beyond lowering BP and albuminuria.
PURPOSE: We assessed the extent of cardiovascular benefit of renin-angiotensin system (RAS) inhibition beyond lowering blood pressure (BP) and albuminuria in type 1 diabetes (T1D). METHODS: This cohort study included 605 T1D participants from the Pittsburgh Epidemiology of Diabetes Complications study without baseline coronary artery disease (CAD). Participant follow-up extended through 25 years. We implemented marginal structural models to estimate total effect of and controlled direct effect by isolating the role of BP or albuminuria in mediating the relation between RAS inhibitors and CAD. RESULTS: Total effect of longitudinal RAS inhibition treatment was associated with 38% decreased CAD risk (HR [95% CI]: 0.62 [0.23, 1.77]). The controlled direct effect of RAS inhibition was a 27% risk reduction (HR: 0.73 [0.20, 2.59]) when isolating the role of BP and 26% risk reduction (HR: 0.74 [0.16, 3.35]) when isolating the role of albuminuria. The mediation proportion for each 10 mm Hg systolic BP and each 1 log unit of albumin excretion rate were 34% and 37%, respectively. CONCLUSION: Our findings suggest that BP regulation and albuminuria reduction can only partially explain cardiovascular benefit of RAS inhibition on CAD in T1D, supporting the assertion that RAS inhibitors provide additional cardioprotection beyond lowering BP and albuminuria.
Authors: Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz Journal: JAMA Date: 2014-02-05 Impact factor: 56.272
Authors: Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright Journal: Hypertension Date: 2017-11-13 Impact factor: 10.190
Authors: T J Orchard; J S Dorman; R E Maser; D J Becker; A L Drash; D Ellis; R E LaPorte; L H Kuller Journal: Diabetes Date: 1990-09 Impact factor: 9.461
Authors: Rachel G Miller; Hemant D Mahajan; Tina Costacou; Akira Sekikawa; Stewart J Anderson; Trevor J Orchard Journal: Diabetes Care Date: 2016-09-21 Impact factor: 19.112
Authors: Cindy L Bryce; Chung Chou H Chang; Yi Ren; Jonathan Yabes; Gabriel Zenarosa; Aditya Iyer; Heather Tomko; Robert H Squires; Mark S Roberts Journal: PLoS One Date: 2018-05-31 Impact factor: 3.240
Authors: Olawale F Ayilara; Lisa Zhang; Tolulope T Sajobi; Richard Sawatzky; Eric Bohm; Lisa M Lix Journal: Health Qual Life Outcomes Date: 2019-06-20 Impact factor: 3.186
Authors: Bruce A Perkins; Leif Erik Lovblom; Sebastien O Lanctôt; Krista Lamb; David Z I Cherney Journal: Diabetologia Date: 2021-03-04 Impact factor: 10.122